Oxaliplatin-induced neuropathy and colo-rectal cancer patient’s quality of life: Practical lessons from a prospective cross-sectional, real-world study

Table 1 Study population

Age of patients	yr
Median	63
Mean	60.6
Minimum	32
Maximum	82
Level of education
Primary education	21%
Upper secondary education	53%
Master/doctoral education	26%
Gender
Male	56.4%
Female	43.6%
Initial stage
Stage II high risk	3.9%
Stage III	34.7%
Stage IV	61.4%
Purpose of treatment
Curative	41.6%
Palliative	56.4%
Undefined	2.0%
Karnofsky performance status
100%	5.9%
90%	45.5%
80%	36.5%
70%	6.9%
60%	5%
Chemotherapy
FOLFOX	37.4%
CapeOX	45.5%
Other	17.1%
Relevant comorbidities
None	55.2%
Diabetes mellitus	10.3%
Alcohol abuse	3.3%
Cardio-vascular diseases	20.1%
Other	11.1%
Diabetes-insulin treatment
Yes	8.4%
No	91.6%

Table 2 Patient’s status at the time of study enrollment

Treatment status
Still going on	35.7%
Stopped due to neuropathy	30.8%
Stopped due to toxicity	16.7%
Finished chemotherapy	16.8%
Types of toxicity
Neuropathy	30.8%
Hematologic	28.2%
Digestive	12.4%
Dermatologic	3.5%
Mixed	25.1%